Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Prospective, Real-World Study Highlights Feasibility of Outpatient Robotic Partial Nephrectomy in Renal Tumors

April 29th 2025

A high proportion of patients with renal tumors were discharged on the same day after receiving robotic partial nephrectomy.

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

April 29th 2025

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC

April 28th 2025

Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.

Dr McGregor on the Outcomes of an Analysis Evaluating the Optimal Dose of Tivozanib in RCC

April 23rd 2025

Bradley McGregor, MD, highlights the outcomes of an exposure response analysis assessing the optimal dose of tivozanib in patients with RCC.

Dr Tykodi on Long-Term Outcomes for Nivolumab Plus Ipilimumab in Favorable-Risk Advanced RCC

April 22nd 2025

Scott Tykodi, MD, PhD, discusses data from CheckMate 214 for nivolumab plus ipilimumab vs sunitinib in favorable-risk advanced RCC.

Dr Bowman on Risk Factors for Kidney Cancer Development

April 21st 2025

I. Alex Bowman, MD, discusses recommended strategies for kidney cancer risk reduction.

Dr Matrana on Factors Influencing Upfront Treatment Approaches for RCC

April 18th 2025

Marc R. Matrana, MD, shares his approach to navigating treatment selection when initiating therapy for patients with RCC.

RCC Treatment Decision-Making Requires a Balance of Efficacy and Individual Patient Considerations

April 16th 2025

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Dr Tykodi on the Selection Between IO/IO and IO/TKI Combinations in Frontline Advanced Clear Cell RCC

April 15th 2025

Scott Tykodi, MD, PhD, discusses key clinical considerations that informing selection between IO/IO and IO/TKI combinations in advanced renal cell carcinoma.

Dr Nguyen on Treatment Selection Considerations for Non–Clear Cell RCC

April 15th 2025

Charles B. Nguyen, MD, details treatment selection in clinical practice for patients with non–clear cell renal cell carcinoma.

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC

April 10th 2025

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Dr Randall on a Survey Outlining Surgical Trial Candidates With RCC and Proximal Femoral Metastases

April 8th 2025

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

Immunogenomic Properties Predict Exceptional Responses to Immune Checkpoint Inhibition in RCC

April 8th 2025

Clonal neoantigen load was significantly associated with promising responses to PD-1/PD-L1 and CTLA-4 combination therapy in RCC.

Dr Albiges on the Efficacy of Lenvatinib Plus Belzutifan in ccRCC

April 4th 2025

Laurence Albiges, MD, PhD, discusses the clinical implications of preliminary efficacy data observed with belzutifan plus lenvatinib in advanced ccRCC.

Kidney Cancer Awareness Month Spotlights Early Symptom Recognition, Current Challenges, and Key Treatment Advancements

April 3rd 2025

I. Alex Bowman, MD, underscores how Kidney Cancer Awareness Month enables earlier disease detection, promotes patient education, and drives vital research.

Dr Merseburger on Real-World Avelumab/Axitinib Discontinuations in Advanced RCC

April 2nd 2025

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Dr Bowman on the Role of Kidney Cancer Awareness in Earlier Detection and Improved Patient Outcomes

March 27th 2025

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Enfortumab Vedotin Shows Manageable Safety in Older Patients With Urothelial Carcinoma

March 24th 2025

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

Residential-Specific Factors and ADT Use Influence HRQOL Outcomes in Bladder and Prostate Cancer

March 22nd 2025

Adjuvant HRQOL outcomes improved in patients with bladder cancer living in rural areas and were worse with ADT plus radiotherapy after prostatectomy.